Jia Wei

Dec 7, 2024 | journalofinfection.com | Jia Wei |Aashna Uppal |Christy Nganjimi |Nicola Jones

The authors regret that an error was found in Table 1 of the original article. The row label for ethnicity was inadvertently reversed. The corrected version of Table 1 with the proper labels is provided in this corrigendum.

Dec 1, 2024 | nature.com | Jie Sun |Jia Wei |Yu-Hua Li |Xiao-bing Huang

AbstractMyeloid sarcoma (MS) is a rare hematological neoplasm with poor prognosis, posing a significant clinical challenge due to the absence of effective and standardized treatments. We conducted a retrospective analysis of 162 MS patients treated at 12 centers to compare outcomes between intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Nov 18, 2024 | nature.com | Jia Wei |Jiandong Zhou |Kevin Yuan |David A Clifton

AbstractAccurately predicting hospital discharge events could help improve patient flow and the efficiency of healthcare delivery. However, using machine learning and diverse electronic health record (EHR) data for this task remains incompletely explored. We used EHR data from February-2017 to January-2020 from Oxfordshire, UK to predict hospital discharges in the next 24 h.

Nov 5, 2024 | mdpi.com | Liyan Yang |Jia Wei

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Sep 24, 2024 | nature.com | Jia Wei |Fang Zhou

AbstractMesothelioma (MESO) is an insidious malignancy with a complex diagnosis and a poor prognosis. Our study unveils Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2) as a valuable diagnostic and prognostic marker for MESO, exploring its role in MESO pathogenesis. We utilised tissue samples and clinicopathologic data to evaluate the diagnostic and prognostic significance of GFPT2 as a biomarker for MESO.